trending Market Intelligence /marketintelligence/en/news-insights/trending/hBFQYdjVPtGUNg7KsJCfSA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Tyme, Eagle Pharmaceuticals enter $20M deal to co-promote cancer therapy in US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Tyme, Eagle Pharmaceuticals enter $20M deal to co-promote cancer therapy in US

Tyme Technologies Inc. and Eagle Pharmaceuticals Inc. entered a $20 million cash-and-stock deal to co-promote Tyme's SM-88 therapy aimed at treating advanced cancers in the U.S.

New York-based Tyme's SM-88 is an experimental compound believed to disrupt protein synthesis of cancer cells, breaking down their key defenses and cell death.

In clinical trials, oral SM-88 has demonstrated complete or partial responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung and blood cancers with minimal adverse events.

Under the agreement, Tyme will receive a $20 million up-front cash payment for 10 million restricted shares of its common stock at $2 per share.

In addition, Tyme will receive $20 million in a milestone payment upon the successful completion of the first of the following three events to occur: meeting the main goal of overall survival in its TYME-88-Panc pivotal trial; meeting the primary endpoint of overall survival in the PanCAN Precision Promise SM-88 registration arm; or the U.S. Food and Drug Administration approval of SM-88 in any cancer.

The milestone payment would be split into a $10 million cash payment and a $10 million investment in Tyme at a 15% premium to the then-prevailing market price. Eagle's shares will be restricted from sale until the earlier of three months after the milestone event or the deal's three-year anniversary.

Woodcliff Lake, N.J.-based Eagle will tackle 25% of the promotional sales effort for SM-88 and receive 15% of the net U.S. revenues. Tyme will handle the rest of the promotional effort, as well as the development, regulatory approval, commercial strategy, marketing, reimbursement and manufacturing of the drug.

Tyme retains the remaining 85% of net U.S. revenues and reserves the right to repurchase Eagle's co-promotion right for $200 million.